Masoprocol
Appearance
(Redirected from Actinex)
![]() | |
Clinical data | |
---|---|
Trade names | Actinex |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Topical |
ATC code | |
Pharmacokinetic data | |
Bioavailability | Very low |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.172 |
Chemical and physical data | |
Formula | C18H22O4 |
Molar mass | 302.370 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Masoprocol is an antineoplastic drug used to treat skin growths caused by sun exposure. It is the meso form of nordihydroguaiaretic acid that is taken by mouth. The substance is being studied in the treatment of prostate cancer.
Masoprocol is also called NDGA, and Actinex.
Mechanism
[edit]Nordihydroguaiaretic acid is an antioxidant, and it may block certain enzymes needed for tumor growth.
It is a lipoxygenase inhibitor.[1]
References
[edit]- ^ Gowri MS, Azhar RK, Kraemer FB, Reaven GM, Azhar S (September 2000). "Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL". American Journal of Physiology. Endocrinology and Metabolism. 279 (3): E593-600. doi:10.1152/ajpendo.2000.279.3.E593. PMID 10950827.
External links
[edit]- MedlinePlus Drug Information
- Actinex entry in the public domain NCI Cancer Dictionary